Q4 and full-year 2025 delivered strong profit and margin improvements, with robust cash flow and reduced net debt. Both Labtech and Medtech segments expanded margins, while acquisitions and portfolio optimization supported future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.